ArticleScientific reports2026
Incidence, time trends and predictors of acute kidney injury in the region of Stockholm, Sweden.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) is a common and potentially serious complication, yet population-level data on its burden and determinants remain limited. We quantified AKI incidence, temporal trends, and risk factors across a complete healthcare system. We conducted a population-based cohort study including all adult residents of Stockholm, Sweden (2017-2021) using the SCREAM project. AKI events requiring hospitalization or occurring during hospital stays were identified using a composite algorithm incorporating laboratory-based KDIGO creatinine criteria, ICD-10 diagnoses, and acute dialysis procedure codes. We calculated annual incidence rates, temporal trends using Poisson regression, and incidence rate ratios for selected demographic, clinical, and laboratory-defined risk factors. Among approximately 1.9 million adults annually, 0.6-0.7% experienced AKI each year (71-95 per 10,000 person-years). AKI occurred in 5.8-7.8% of hospitalizations, with only 30% reaching KDIGO stage 2-3. From 2017 to 2021, AKI incidence increased by 26% (95% CI 1.23-1.29). Populations at highest risk of AKI were largely consistent over the years, and included older adults, men, and individuals with uncontrolled diabetes, prior AKI, hypertension, heart failure, kidney transplantation, and multiple myeloma. Lower eGFR and higher albuminuria were associated with markedly higher AKI risk in a graded manner. COVID-19 infection was associated with a six-fold higher AKI risk in 2020, but marked attenuation in 2021 suggests it does not explain the overall upward trend. This region-wide analysis quantifies the contemporary burden of AKI and identifies high-risk populations that may benefit from targeted prevention and monitoring strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.